Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing clinical case observations of genetic hormone deficiencies and animal models
PubMed 15621211 · doi:10.1016/j.mad.2004.08.022
What was done
This narrative review synthesized clinical observations of untreated patients with genetic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) deficiencies—including isolated GH deficiency (GH gene deletion), multiple pituitary hormone deficiency (PROP-1 mutation), and Laron syndrome (GH receptor mutation)—alongside findings from corresponding rodent knockout and transgenic models.
What was found
Patients with untreated GH or IGF-1 deficiencies reached long lifespans of 80 to 90 years despite displaying phenotypic features of early aging, including wrinkled skin, obesity, insulin resistance, and osteopenia. Rodent models with genetic GH deficiency (Snell, Ames, and Laron knockout mice) demonstrated statistically significant increases in longevity relative to normal controls. Conversely, excess GH exposure in GH-transgenic mice and human acromegaly was associated with premature mortality. Specific quantitative hazard ratios or sample sizes were not reported in the abstract.
Why it matters
These observations challenge the premise of adult GH supplementation as an anti-aging therapy by indicating that reduced GH/IGF-1 signaling does not shorten lifespan and may confer survival advantages.
Limits
The abstract describes a narrative overview rather than a systematic review or meta-analysis. Sample sizes and exact mortality rates are omitted, and findings in rare congenital single-gene mutations may not translate directly to physiological aging or adult pharmacological interventions.
Cited by
- context Models and cohorts with growth hormone deficiency exhibit extended lifespan.